The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes
Status:
Completed
Trial end date:
2019-01-13
Target enrollment:
Participant gender:
Summary
The overall objective is to compare the short-term (3 months) effectiveness of three
glucose-lowering interventions (dapagliflozin, metformin and physical activity) on glucose
variability, body composition, and cardiometabolic risk factors in overweight or obese
individuals with pre-diabetes (HbA1c 5.7-6.4% / 39-47 mmol/mol).
Phase:
Phase 2
Details
Lead Sponsor:
Steno Diabetes Center Steno Diabetes Center Copenhagen
Collaborators:
AstraZeneca Bayer Rigshospitalet, Denmark The Novo Nordic Foundation